Clinical Trial Update: A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating SAR444245 in combination with cemiplimab for advanced skin cancers (malignant melanoma and squamous cell carcinoma of the skin) has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Cemiplimab (cemiplimab)
• SAR444245

Snippet

Sponsor: Sanofi | Conditions: Malignant Melanoma, Squamous Cell Carcinoma of Skin | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-02-04